Percentage of total serum bile acids | |||||
---|---|---|---|---|---|
Patient group | CA | DCA | CDCA | UDCA | LCA |
Control subjects (n=16) | 33 (6.3) | 13 (1.5)1-150 | 49 (5.9)1-152 | 5.5 (1.2) | 0.4 (0.1) |
Acromegalic patients | |||||
Untreated with OT (n=16) | 44 (5.4) | 18 (2.7)1-151 | 33 (4.2) | 5.2 (1.2) | 0.6 (0.2) |
Treated with LTOT (n=16) | 40 (3.0) | 26 (2.3) | 31 (3.1) | 3.1 (1.0) | 0.4 (0.1) |
Patients with simple constipation (n=16) | 35 (3.6) | 27 (2.3) | 33 (2.4) | 4.9 (1.0) | 0.4 (0.1) |
Acromegalic patients—paired study (n=9) | |||||
Before OT | 55 (6.6)1-153 | 15 (3.3)1-154 | 27 (5.2) | 3.2 (1.1) | 0.43 (0.1) |
During OT | 43 (4.1) | 29 (2.7) | 26 (3.3) | 3.1 (1.0) | 0.46 (0.2) |
Results expressed as mean (SEM). Unless otherwise indicated, the differences between the means were not statistically significant.
↵1-150 p<0.001 versus acromegalic patients on long term octreotide and patients with simple constipation.
↵1-151 p<0.05 versus acromegalic patients on long term octreotide and patients with simple constipation.
↵1-152 p<0.05 versus acromegalic patients untreated with octreotide, acromegalic patients on long term octreotide, and patients with simple constipation.
↵1-153 p<0.05 versus acromegalic patients during octreotide treatment.
↵1-154 p<0.001 versus acromegalic patients during octreotide treatment.
OT, octreotide; LTOT, long term octreotide; CA, cholic acid; DCA, deoxycholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid; LCA, lithocholic acid.